Why Boston Scientific Corporation’s (BSX) Stock Is Up 5.35%
As of Friday, August 21, Boston Scientific Corporation’s BSX share price has surged by 5.35%, which has investors questioning if this is right time to sell.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Jenna Brashear
Jenna Brashear
Michael Rose
Cynthia McLaughlin
| Share Statistics | BSX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $61,737.2 | $389.6 | 95% |
|
| Shares Out (Mil) | 1,474.8 | 40.9 | 96% |
|
| Institutional Ownership | 99.8% | 82.8% | 94% |
|
| Float (Mil) | 1,445.0 | 35.5 | 93% |
|
| Beta | 0.57 | 0.85 | 33% |
|
| Avg Daily Volume (000s) | 18,769 | 298 | 98% |
|
| Price Change (52-week) |
(55.6%) | 63.7% | 16% |
|
| Growth | BSX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.2% | 11.8% | 73% |
|
| Net Income (5yr) | 106.3% | (5.6%) | 99% |
|
| EPS (5yr) | 91.8% | 10.2% | 99 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 1.2% | (15.5%) | 65% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 22 | 25 | 26 | |
| Current EPS | $0.761 | $3.265 | $3.410 | |
| Month Ago EPS | $0.805 | $3.304 | $3.433 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $0.839 | $3.363 | $3.721 | |
| Year/Year Chg | 24.8% | 68.3% | 94.1% | |
| Financials | BSX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $20,996 | $141 | 91% |
|
| Net Income (TTM) (Mil) | $3,674 | ($9) | 95% |
|
| EPS (TTM) | $2.483 | ($0.400) | 75% |
|
| Operating Cash Flow (TTM) (Mil) | $4,529 | ($2) | 94% |
|
| Net Cash Flow (TTM) (Mil) | $12 | $1 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $10,915 | $26 | 92% |
|
| Enterprise Value (Q1) (Mil) | $82,426 | $409 | 95% |
|
| Valuation | BSX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.47 | 2.73 | 60% |
|
| P/E | 17.3 | 25.0 | 47% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.2 | 1.4 | 8% |
|
| Ratios | BSX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.2% | 58.7% | 80% |
|
| Net Margin | 17.5% | (6.9%) | 76% |
|
| ROA | 8.5% | (12.2%) | 84% |
|
| ROE | 15.5% | (10.7%) | 72% |
|
| Liabilities to Assets | 44.3% | 47.2% | 35% |
|
| F-Score | 8 | 4 | 93% |
|
Boston Scientific Corporation did not pass any screens on 10/2/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors